Science & Technology

Channels: Science & Technology | Financial Markets | Artificial Intelligence | Blockchain


CureVac Granted Manufacturing Authorization for its Third GMP Production Suite

[2019.12.02, Mon 12:03] TÜBINGEN, Germany and BOSTON, Dec. 02, 2019 - CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, announced today it received the manufacturing authorization for clinical trial materials produced under Good Manufacturing Practice from the competent national authority, Regierungspräsidium Tübingen technology with more than 19 years of expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. To date, CureVac has received approximately $420 million in equity investments, including significant investments from SAP founder Dietmar Hopp's dievini and the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, Eli Lilly & Co, CRISPR Therapeutics, the Bill & Melinda Gates Foundation, and others.
Read on GlobeNewswire >   Google the news >>

<< Back


(c) 2019 Geo Glance